在 dystonia 中针对神经递质系统的进步
Dora Steel1, Kimberley M Reid2, Antonio Pisani3
1UCL GOS Institute of Child Health (Zayed Centre for Research into Rare Diseases in Children), London, United Kingdom; Great Ormond Street Hospital for Children, London, United Kingdom.
International review of neurobiology
|July 23, 2023
概括
腹痛包括非自愿的肌肉收缩,导致异常姿势. 本综述探讨了神经递质作用和当前/新兴疗法,包括遗传疗法,用于管理这种神经疾病.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 腹痛是一种神经系统疾病,导致肌肉非自愿收缩,异常姿势和重复运动.
- 它导致全球显著的神经疾病,目前的治疗方法在最佳的症状控制和副作用管理方面面临挑战.
- 药物治疗通常针对中枢神经系统的神经递质,但精确的调制仍然复杂.
研究的目的:
- 审查关键神经递质在 dystonia 的生理作用.
- 检查针对 dystonia 的现有和新型药物剂.
- 讨论目前和新兴的基因疗法来治疗 dystonia.
主要方法:
- 对神经递质的生理学的综述,包括多巴胺,诺阿德拉林,血清素,乙胆,GABA,谷氨酸,腺素和大麻素.
- 对已建立和正在开发的药理疗法进行分析.
- 探索治疗 dystonia 的基因疗法.
主要成果:
- 多巴胺,上腺素,血清素,乙胆,GABA,谷氨酸,腺和大麻素在 dystonia 病理生理学中起着至关重要的作用.
- 现有的药物提供症状缓解,但往往有局限性;新型药物显示出希望.
- 基因疗法代表了治疗遗传性 dystonia 形式的潜在未来方向.
结论:
- 了解神经递质系统是开发有效 dystonia 治疗的关键.
- 药理学和遗传学方法的结合可以提供更好的结果.
- 对新型药物和基因疗法的持续研究有望为更好的 dystonia 管理提供希望.
相关概念视频
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
708
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
708
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
716
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
716
01:24Parkinson's Disease: Treatment
301
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
301
01:26Neurochemical Transmission: Sites of Drug Action
2.5K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
2.5K
01:15Parkinson's Disease: Overview
601
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
601